A randomised trial to compare the safety, tolerability and efficacy of three drug combinations for intermittent preventive treatment in children

Kalifa Bojang, Francis Akor, Ousman Bittaye, David Conway, Christian Bottomley, Paul Milligan, Brian Greenwood, Kalifa Bojang, Francis Akor, Ousman Bittaye, David Conway, Christian Bottomley, Paul Milligan, Brian Greenwood

Abstract

Background: Results from trials of intermittent preventive treatment (IPT) in infants and children have shown that IPT provides significant protection against clinical malaria. Sulfadoxine-pyrimethamine (SP) given alone or in combination with other drugs has been used for most IPT programmes. However, SP resistance is increasing in many parts of Africa. Thus, we have investigated whether SP plus AQ, SP plus piperaquine (PQ) and dihydroartemisinin (DHA) plus PQ might be equally safe and effective when used for IPT in children in an area of seasonal transmission.

Methods: During the 2007 malaria transmission season, 1008 Gambian children were individually randomized to receive SP plus amodiaquine (AQ), SP plus piperaquine (PQ) or dihydroartemisinin (DHA) plus PQ at monthly intervals on three occasions during the peak malaria transmission season. To determine the risk of side effects following drug administration, participants in each treatment group were visited at home three days after the start of each round of drug administration and a side effects questionnaire completed. To help establish whether adverse events were drug related, the same questionnaire was administered to 286 age matched control children recruited from adjacent villages. Morbidity was monitored throughout the malaria transmission season and study children were seen at the end of the malaria transmission season.

Results: All three treatment regimens showed good safety profiles. No severe adverse event related to IPT was reported. The most frequent adverse events reported were coughing, diarrhoea, vomiting, abdominal pain and loss of appetite. Cough was present in 15.2%, 15.4% and 18.7% of study subjects who received SP plus AQ, DHA plus PQ or SP plus PQ respectively, compared to 19.2% in a control group. The incidence of malaria in the DHA plus PQ, SP plus AQ and SP plus PQ groups were 0.10 cases per child year (95% CI: 0.05, 0.22), 0.06 (95% CI: 0.022, 0.16) and 0.06 (95% CI: 0.02, 0.15) respectively. The incidence of malaria in the control group was 0.79 cases per child year (0.58, 1.08).

Conclusion: All the three regimens of IPT in children were safe and highly efficacious

Trial registration: ClinicalTrials.gov NCT00561899.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1. Trial profile.
Figure 1. Trial profile.

References

    1. WHO. Experts Committee report on Malaria. 2000. pp. 1–74. Report. Geneva, WHO.
    1. Schellenberg D, Cissé B, Menendez C. The IPTi Consortium: research for policy and action. Trends Parasitol. 2006;22:296–300.
    1. Cissé B, Sokhna C, Boulanger D, acqueline Milet, El Hadj Bâ, et al. Seasonal intermittent preventive treatment with artesunate and sulfadoxine-pyrimethamine for prevention of malaria in Senegalese children: a randomised, placebo-controlled, doubleblind trial. Lancet. 2006;367:659–667.
    1. Dicko A, Sagara I, Sissoko MS, Guindo O, Diallo AI, et al. Impact of intermittent preventive treatment with sulphadoxine-pyrimethamine targeting the transmission season on the incidence of clinical malaria in children in Mali. Malar J . 2008;7:123.
    1. Sokhna C, Cissé B, Bâ el H, Milligan P, Hallett R, et al. A trial of the efficacy, safety and impact on drug resistance of four drug regimens for seasonal intermittent preventive treatment for malaria in Senegalese children. PLoS ONE. 2008;3:e1471.
    1. Kweku M, Liu D, Adjuik M, Binka F, Seidu M, et al. Seasonal intermittent preventive treatment for the prevention of anaemia and malaria in Ghanaian children: a randomized, placebo controlled trial. PLoS ONE. 2008;3:e4000.
    1. Greenwood BM, Pickering H. A review of the epidemiology and control of malaria in The Gambia, West Africa. Tran Roy Soc Trop Med Hyg. 1993;87(suppl 2):3–11.
    1. Thomson MC, D'Alessandro U, Bennet S, et al. Malaria prevalence is inversely related to vector density in The Gambia, West Africa. Tran Roy Soc Trop Med Hyg. 1994;88:638–43.
    1. Dunyo S, Ord R, Hallett R, Jawara M, Walraven G, et al. Randomised Trial of Chloroquine/Sulphadoxine-Pyrimethamine in Gambian Children with Malaria: Impact against Multidrug-Resistant P. falciparum. PLoS Clin Trials. 2006;1:e14.
    1. Greenwood BM, Armstrong JRM. Comparison of two simple methods for determining malaria parasite density. Tran Roy Soc Trop Med Hyg. 1991;85:186–88.
    1. Olliaro P, Nevill C, LeBras J, Ringwald P, Mussano P, et al. Systematic review of amodiaquine treatment in uncomplicated malaria. Lancet. 1996;348:1196–201.
    1. Phillips-Howard PA, L. W. Serious adverse drug reactions to pyrimethamine-sulphadoxine, pyrimethamine-dapsone and to amodiaquine in Britain. J R Soc Med. 1990;83:82–5.
    1. Pussard E, Verdier F, Faurisson F, Scherrmann JM, Le Bras J, Blayo MC. Disposition of monodesethylamodiaquine after a single oral dose of amodiaquine and three regimens for prophylaxis against Plasmodium falciparum malaria. Eur J Clin Pharmacol. 1987;33:409–414.
    1. White NJ. Intermittent presumptive treatment for malaria. PLoS Med. 2005;2:e3.
    1. Greenwood B. Intermittent preventive antimalarial treatment in infants. Clin Infect Dis. 2007;45:26–28.
    1. Myint HY, Ashley EA, Day NP, Nosten F, White NJ. Efficacy and safety of dihydroartemisinin-piperaquine. Trans R Soc Trop Med Hyg. 2007;101:858–866.
    1. Steketee RW, Wirima JJ, Slutsker L, Roberts JM, Khoromana CO, et al. Malaria parasite infection during pregnancy and at delivery in mother, placenta, and newborn: efficacy of chloroquine and mefloquine in rural Malawi. Am J Trop Med Hyg. 1996;55(1) Suppl:24–32.
    1. Gosling R, Chandramohan D, Greenwood B. Drug options for intermittent preventive treatment for malaria in infants in an area with high resistance to sulfadoxine/pyrimethamine: an evaluation of short and long-acting antimalarial drugs, submitted

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe